Wang Liqiang

Wang Liqiang (chief executive) discloses dealings in 2 companies, chiefly RemeGen Co., Ltd. and RemeGen Co., Ltd. - H Shares. Between 29 September 2025 and 22 July 2026, the trades on record add up to 20 filings.

On the open market, the record shows 5 purchases and 14 sales worth €7.7M. No amount is published for 7 filings, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2026, the count stands at 5 purchases and 14 sales.

Across 5 purchases, this insider has always bought alone, with no colleague buying within 30 days.

Most recently, on 24 July 2026, the filings show an open-market sale worth €4,072 in RemeGen Co., Ltd. - H Shares. The clock since the last published purchase (15 June 2026) now reads 131 days. Filings reach the HKEX feed a median of 6 days after the trade. That lag is the time during which only the insider knows about the trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by HKEX and describes the past, not future prices; it is not investment advice.